Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

NCT05274269 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

307

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: ELX/TEZ/IVA
DRUG: IVA
OTHER: Placebo (matched to ELX/TEZ/IVA)
OTHER: Placebo (matched to IVA)

Sponsor

Vertex Pharmaceuticals Incorporated